ES2135342A1 - Procedimiento para prevenir el cancer de mama. - Google Patents

Procedimiento para prevenir el cancer de mama.

Info

Publication number
ES2135342A1
ES2135342A1 ES09702224A ES9702224A ES2135342A1 ES 2135342 A1 ES2135342 A1 ES 2135342A1 ES 09702224 A ES09702224 A ES 09702224A ES 9702224 A ES9702224 A ES 9702224A ES 2135342 A1 ES2135342 A1 ES 2135342A1
Authority
ES
Spain
Prior art keywords
raloxifene
prophylaxis
breast cancer
administration
relating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES09702224A
Other languages
English (en)
Other versions
ES2135342B1 (es
Inventor
Frederic Jay Cohen
Joan Ellen Glusman
Ronald Keith Knickerbocker
Nikolaus Thomas Nickelsen
Teri Janine Scott
Robert Stephen Eckert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27268608&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2135342(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9624800.0A external-priority patent/GB9624800D0/en
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of ES2135342A1 publication Critical patent/ES2135342A1/es
Application granted granted Critical
Publication of ES2135342B1 publication Critical patent/ES2135342B1/es
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Uso del raloxifeno o una sal o solvato del mismo en la preparación de un medicamento para prevenir el cáncer de mama. Un procedimiento para prevenir el cáncer de mama, que comprende administrar durante un período suficiente a un ser humano que lo necesite una cantidad eficaz de un compuesto que tiene la fórmula I, y las sales y solvatos farmacéuticamente aceptables del mismo.
ES009702224A 1996-10-30 1997-10-28 Uso del raloxifeno o una sal o salvato del mismo en la preparacion de un medicamento para prevenir el cancer de mama. Expired - Fee Related ES2135342B1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2985096P 1996-10-30 1996-10-30
GBGB9624800.0A GB9624800D0 (en) 1996-11-29 1996-11-29 Methods of preventing breast cancer
US4026097P 1997-03-10 1997-03-10

Publications (2)

Publication Number Publication Date
ES2135342A1 true ES2135342A1 (es) 1999-10-16
ES2135342B1 ES2135342B1 (es) 2000-05-16

Family

ID=27268608

Family Applications (4)

Application Number Title Priority Date Filing Date
ES009702224A Expired - Fee Related ES2135342B1 (es) 1996-10-30 1997-10-28 Uso del raloxifeno o una sal o salvato del mismo en la preparacion de un medicamento para prevenir el cancer de mama.
ES09702225A Withdrawn ES2135343A1 (es) 1996-10-30 1997-10-28 Mejoras en la profilaxis del cancer de mama, o relacionadas con esta.
ES03102726T Expired - Lifetime ES2271476T3 (es) 1996-10-30 1997-10-29 Procedimientos de prevencion de cancer de mama por administracion de raloxifeno.
ES97308588T Expired - Lifetime ES2197312T3 (es) 1996-10-30 1997-10-29 Mejoras en o en relacion con la profilaxis del cancer de mama por administracion de raloxifeno.

Family Applications After (3)

Application Number Title Priority Date Filing Date
ES09702225A Withdrawn ES2135343A1 (es) 1996-10-30 1997-10-28 Mejoras en la profilaxis del cancer de mama, o relacionadas con esta.
ES03102726T Expired - Lifetime ES2271476T3 (es) 1996-10-30 1997-10-29 Procedimientos de prevencion de cancer de mama por administracion de raloxifeno.
ES97308588T Expired - Lifetime ES2197312T3 (es) 1996-10-30 1997-10-29 Mejoras en o en relacion con la profilaxis del cancer de mama por administracion de raloxifeno.

Country Status (43)

Country Link
US (2) US6303634B1 (es)
EP (3) EP0839533A1 (es)
JP (2) JPH10147530A (es)
CN (2) CN1182591A (es)
AP (1) AP971A (es)
AR (2) AR013864A1 (es)
AT (2) ATE338551T1 (es)
AU (3) AU5005697A (es)
BE (2) BE1011382A5 (es)
BG (1) BG63841B1 (es)
BR (1) BR9712703A (es)
CA (2) CA2219377A1 (es)
CH (2) CH691847A5 (es)
CZ (2) CZ341297A3 (es)
DE (2) DE69736644T2 (es)
DK (2) DK0839532T3 (es)
EA (2) EA006083B1 (es)
EE (1) EE03663B1 (es)
ES (4) ES2135342B1 (es)
FR (2) FR2756490B1 (es)
GB (3) GB2318734B (es)
GE (1) GEP20032910B (es)
GR (2) GR970100409A (es)
HU (2) HUP9701778A3 (es)
IE (2) IE970772A1 (es)
IL (2) IL122025A (es)
IS (1) IS5035A (es)
IT (2) IT1298470B1 (es)
LU (2) LU90157B1 (es)
LV (1) LV12353B (es)
MY (1) MY121623A (es)
NL (2) NL1007386C2 (es)
NO (2) NO322468B1 (es)
NZ (1) NZ329042A (es)
PT (2) PT839532E (es)
RO (1) RO120813B1 (es)
SG (2) SG72765A1 (es)
SI (3) SI20107A (es)
SK (1) SK287047B6 (es)
TR (1) TR199900951T2 (es)
UA (1) UA46762C2 (es)
WO (2) WO1998018449A1 (es)
YU (1) YU42397A (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458811B1 (en) * 1996-03-26 2002-10-01 Eli Lilly And Company Benzothiophenes formulations containing same and methods
GB9624800D0 (en) * 1996-11-29 1997-01-15 Lilly Co Eli Methods of preventing breast cancer
FI982733L (fi) 1998-12-17 2000-06-18 Orion Yhtymae Oyj Trifenyylietyleeniantiestrogeenien liukoisia koostumuksia
FI109332B (fi) 1998-12-17 2002-07-15 Orion Yhtymae Oyj Toremifeenin liukoisia koostumuksia
EP1395563B1 (en) 2001-05-22 2006-03-29 Eli Lilly And Company 2-substituted 1,2,3,4-tetrahydroquinolines and derivatives thereof, compositions and methods
JP2004531559A (ja) 2001-05-22 2004-10-14 イーライ・リリー・アンド・カンパニー エストロゲン欠乏または内因性エストロゲンに対する異常な生理反応に関連する疾患を抑制するためのテトラヒドロキノリン誘導体
US20040225200A1 (en) * 2003-05-09 2004-11-11 Edmundson Catherine M. System and method of analyzing the health of a population
GR1005694B (el) * 2005-06-08 2007-10-22 Αλεξης Μιχαηλ Ιστοειδικα αντιοιστρογονα ειδικα για τον αλφα υποδοχεα των οιστρογονων
UA97813C2 (uk) * 2006-12-05 2012-03-26 Янссен Фармацевтика Н.В. Фумаратна сіль (альфа s, бета r)-6-бром-альфа-[2-(диметиламіно)етил]-2-метоксі-альфа-1-нафталеніл-бета-феніл-3-хінолінетанолу
MD36Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului ductal in situ neinvaziv al glandei mamare
MD35Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de apreciere a riscului dezvoltării carcinomului neinvaziv in situ al glandei mamare
MD23Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului lobular in situ neinvaziv al glandei mamare
MD24Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului neinvaziv al glandei mamare
WO2011099942A1 (en) 2010-02-09 2011-08-18 Silverstone Pharma New addition salts of raloxifene, process for the preparation thereof and use thereof in therapy
CN102973573B (zh) * 2012-11-28 2015-04-08 玉林师范学院 一种人乳腺癌细胞抑制剂及制备方法
CN103830197A (zh) * 2014-03-14 2014-06-04 崔书豪 一种盐酸雷洛昔芬分散片及其制备方法
CN116650484A (zh) * 2023-05-11 2023-08-29 南通大学 一种乳腺癌相关蛋白的抑制剂及其应用
MX2023013107A (es) * 2023-11-06 2025-06-02 Centro De Investig Y De Estudios Avanzados Del I P N Composiciones sinergicas de loratadina-raloxifeno-sorafenib para el tratamiento de cancer hepatico.

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
EP0652004A1 (en) * 1993-10-15 1995-05-10 Eli Lilly And Company Methods for treating resistant neoplasms
EP0674903A1 (en) * 1994-03-02 1995-10-04 Eli Lilly And Company Raloxifene for inhibiting bone loss and lowing serum cholesterol
EP0680758A1 (en) * 1994-05-05 1995-11-08 Eli Lilly And Company Pharmaceutical compositions containing tamoxifen or analogs and raloxifene or analogs
WO1996022771A1 (en) * 1995-01-25 1996-08-01 Eli Lilly And Company Methods of inhibiting environmental estrogens

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4656187A (en) * 1981-08-03 1987-04-07 Eli Lilly And Company Treatment of mammary cancer
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体
CA2143263C (en) * 1994-03-02 2002-01-08 Kerry John Hartauer Orally administrable raloxifene formulations
US5821254A (en) 1995-02-17 1998-10-13 The United States Of America As Represented By The Department Of Health And Human Services Uses of 9-cis-retinoic acids and derivatives thereof alone or in combination with antineoplastic agents in the prevention or treatment of cancer
EA001257B1 (ru) * 1996-03-26 2000-12-25 Эли Лилли Энд Компани Бензотиофены, содержащие их фармацевтические композиции и способы лечения патологических состояний с их использованием

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
EP0652004A1 (en) * 1993-10-15 1995-05-10 Eli Lilly And Company Methods for treating resistant neoplasms
EP0674903A1 (en) * 1994-03-02 1995-10-04 Eli Lilly And Company Raloxifene for inhibiting bone loss and lowing serum cholesterol
EP0680758A1 (en) * 1994-05-05 1995-11-08 Eli Lilly And Company Pharmaceutical compositions containing tamoxifen or analogs and raloxifene or analogs
WO1996022771A1 (en) * 1995-01-25 1996-08-01 Eli Lilly And Company Methods of inhibiting environmental estrogens

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANZANO et al. Chemoprevention of mammary carcinogenesis in the rat: combined use of raloxifene and 9-cis-retinoic acid, Journal of the National Cancer Institute, Vol. 88, no 2, Enero 1996, paginas 123-125. *
JORDAN et al. Alternate Antiestrogens and approaches to the prevention of breast cancer, Journal of Cellular Biochemistry, Vol. 58, no 5.22, 1995, paginas 51-57, resumen; paginas 54,55; figura 3. *

Also Published As

Publication number Publication date
HUP9701777A3 (en) 1999-07-28
GB2318733A (en) 1998-05-06
EA002054B1 (ru) 2001-12-24
SI1369115T1 (sl) 2006-12-31
IS5035A (is) 1999-04-27
SI0839532T1 (en) 2003-10-31
BE1011381A5 (fr) 1999-08-03
LU90158B1 (fr) 1998-06-02
MX9708340A (es) 1998-08-30
FR2756490B1 (fr) 2003-06-20
AR010538A1 (es) 2000-06-28
ES2135342B1 (es) 2000-05-16
ES2197312T3 (es) 2004-01-01
CN1182591A (zh) 1998-05-27
ATE239475T1 (de) 2003-05-15
NO322468B1 (no) 2006-10-09
US6303634B1 (en) 2001-10-16
IL122026A0 (en) 1998-03-10
DK0839532T3 (da) 2003-08-25
DE69736644T2 (de) 2007-10-25
FR2755014B1 (fr) 1999-02-05
GB9722796D0 (en) 1997-12-24
SI20107A (sl) 2000-06-30
HK1010495A1 (en) 1999-06-25
SG72765A1 (en) 2000-05-23
HUP9701777A2 (hu) 1999-06-28
GR1003189B (el) 1999-09-01
BG63841B1 (bg) 2003-03-31
CZ341297A3 (cs) 1998-05-13
JPH10147530A (ja) 1998-06-02
EA006083B1 (ru) 2005-08-25
DK1369115T3 (da) 2007-01-02
UA46762C2 (uk) 2002-06-17
PT1369115E (pt) 2006-12-29
MY121623A (en) 2006-02-28
NO974973D0 (no) 1997-10-28
BR9712703A (pt) 1999-10-26
CA2219377A1 (en) 1998-04-30
WO1998018449A1 (en) 1998-05-07
GB9722801D0 (en) 1997-12-24
DE69736644D1 (de) 2006-10-19
HU9701777D0 (en) 1997-12-29
HU9701778D0 (en) 1997-12-29
IE970773A1 (en) 2000-02-09
HUP9701778A3 (en) 1999-06-28
SK55999A3 (en) 2000-06-12
CN1182590A (zh) 1998-05-27
CH693820A5 (fr) 2004-02-27
CZ300261B6 (cs) 2009-04-01
LV12353B (en) 2000-02-20
EP1369115B1 (en) 2006-09-06
EP0839532B1 (en) 2003-05-07
JPH10147529A (ja) 1998-06-02
GR970100409A (el) 1998-06-30
NO974972D0 (no) 1997-10-28
NZ329042A (en) 1999-08-30
HUP9701778A2 (hu) 1999-01-28
BG103369A (en) 2000-05-31
GR970100408A (el) 1998-06-30
SK287047B6 (sk) 2009-10-07
LU90157B1 (fr) 1998-06-02
ATE338551T1 (de) 2006-09-15
CH691847A5 (fr) 2001-11-15
AP971A (en) 2001-05-30
EP0839532A1 (en) 1998-05-06
ES2271476T3 (es) 2007-04-16
CA2219070C (en) 2007-12-18
US20020019418A1 (en) 2002-02-14
AU5005697A (en) 1998-05-22
AU5005197A (en) 1998-05-22
IE970772A1 (en) 2000-02-09
AU4364897A (en) 1998-05-07
EP1369115A1 (en) 2003-12-10
EA199900431A1 (ru) 1999-10-28
IL122025A (en) 2003-01-12
FR2755014A1 (fr) 1998-04-30
NL1007387C2 (nl) 1998-05-14
NO974972L (no) 1998-05-04
ITMI972434A1 (it) 1999-04-29
GB2318734A (en) 1998-05-06
AR013864A1 (es) 2001-01-31
EE9900162A (et) 1999-12-15
AU731388B2 (en) 2001-03-29
NL1007386C2 (nl) 1998-05-14
PT839532E (pt) 2003-09-30
GEP20032910B (en) 2003-03-25
EP0839533A1 (en) 1998-05-06
LV12353A (lv) 1999-10-20
WO1998018325A1 (en) 1998-05-07
DE69721692T2 (de) 2004-03-25
GB2318734B (en) 1999-12-01
CA2219070A1 (en) 1998-04-30
IL122025A0 (en) 1998-03-10
AU4364797A (en) 1998-05-07
EA200100716A1 (ru) 2002-06-27
MX9708341A (es) 1998-08-30
YU42397A (sh) 2000-10-30
RO120813B1 (ro) 2006-08-30
AP9901494A0 (en) 1999-03-31
FR2756490A1 (fr) 1998-06-05
DE69721692D1 (de) 2003-06-12
BE1011382A5 (fr) 1999-08-03
TR199900951T2 (xx) 1999-07-21
ES2135343A1 (es) 1999-10-16
ITMI972433A1 (it) 1999-04-29
EE03663B1 (et) 2002-04-15
CZ341197A3 (cs) 1998-05-13
SG83672A1 (en) 2001-10-16
GB9911557D0 (en) 1999-07-21
IT1298470B1 (it) 2000-01-10

Similar Documents

Publication Publication Date Title
ES2135343A1 (es) Mejoras en la profilaxis del cancer de mama, o relacionadas con esta.
SG45315A1 (en) Improvements in or relating to benzothiopenes
TW271395B (es)
BG103740A (en) Phytostyrene composition for the prevention of the alzheimer's disease
UA39158C2 (uk) Похідні n4-оксикарбоніл-5'-дезокси-5-фторцитидину та фармацевтичний препарат на їх основі
BG103882A (en) Voriconazol-containing pharmaceutical compositions
MX9804588A (es) Uso de composiciones que comprenden blanqueador de halogeno para suavidad mejorada a la piel.
AU649082B2 (en) Progestagen-only contraceptive
BG101875A (en) New cryptoficins and method for their preparation
BG105197A (en) Polymorph form of a medicament
GR3031119T3 (en) A pharmaceutical composition comprising a phosphosugar
JPH0784481B1 (es)
BG104179A (en) Phanquinon administration for the treatment of the alzheimer's disease
DE3263832D1 (en) Gallium chloride, an anti-cancer drug
GB9420747D0 (en) 1,5 benzodiazepine derivatives
GB1512771A (en) Piperazinyluracil salt
NZ336321A (en) Use of benzothiophene (raloxifene) for treating breast cancer
GB8908906D0 (en) Therapeutic compounds,compositions & uses thereof
FR2412306A1 (fr) Systeme de bras pour fauteuils de traitement, notamment pour fauteuils dentaires
MX9707735A (es) Nuevo uso de (s)-adenosil-l-metionina (same).
TH34521A (th) การปรับปรุงในหรือสัมพันธ์กับการป้องกันโรคมะเร็งเต้านม
MX9709683A (es) Uso de derivados de vitamina d4 para tratamiento contra el cancer.
RU97118477A (ru) Применение ралоксифена или его фармацевтически приемлемой соли в профилактике рака молочной железы
MY117590A (en) Orally administerable pharmaceutical formulations
ES8507140A1 (es) Procedimiento para la preparacion del citrato de la (-) vinburnina

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 19991016

Kind code of ref document: A1

Effective date: 19991016

FD1A Patent lapsed

Effective date: 20100616